Source comparison
Tesamorelin vs Other Peptides: Timeline Comparison
Tesamorelin GHRH agonist (stimulates endogenous GH pulses) 12–16 weeks for measurable VAT reduction 26 weeks High. Preferentially targets visceral depots CJC-1295 + Ipamorelin GHRH + ghrelin mimetic (combined GH release) 8–12 weeks for body composition changes
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH agonist (stimulates endogenous GH pulses)
- 12–16 weeks for measurable VAT reduction
- 26 weeks
- High. Preferentially targets visceral depots
- CJC-1295 + Ipamorelin
- GHRH + ghrelin mimetic (combined GH release)
- 8–12 weeks for body composition changes
- 16–20 weeks
- Moderate. Affects both visceral and subcutaneous fat
- Sermorelin
- GHRH agonist (shorter half-life than tesamorelin)
- 10–14 weeks
- 20–24 weeks
- Moderate. Less selective than tesamorelin
- AOD-9604
- GH fragment (lipolytic fragment only)
- 6–8 weeks for fat loss
- 12–16 weeks
- Low. Targets subcutaneous fat more than visceral
- Tesamorelin's longer timeline to measurable effect reflects its specificity. Unlike broad-spectrum fat loss compounds, it works through a highly targeted pathway that requires sustained activation before structural changes occur. The trade-off for that specificity is patience. Results come later but are more predictable and reproducible across patient populations.